Regulatory perspectives on data monitoring.
暂无分享,去创建一个
[1] L Wasserman,et al. Robust Bayesian methods for monitoring clinical trials. , 1995, Statistics in medicine.
[2] A. Goldman. Issues in designing sequential stopping rules for monitoring side effects in clinical trials. , 1987, Controlled clinical trials.
[3] A I Goldman,et al. Optimal continuous sequential boundaries for monitoring toxicity in clinical trials: a restricted search algorithm. , 2001, Statistics in medicine.
[4] F. Rockhold,et al. Data monitoring and interim analyses in the pharmaceutical industry: ethical and logistical considerations. , 1993, Statistics in medicine.
[5] D. DeMets,et al. The data and safety monitoring board and acquired immune deficiency syndrome (AIDS) clinical trials. , 1995, Controlled clinical trials.
[6] Pma Biostatistics. Interim analysis in the pharmaceutical industry , 1993 .
[7] K K Lan,et al. Monitoring boundaries for adverse effects in long-term clinical trials. , 1986, Controlled clinical trials.
[8] R. O’Neill. Some FDA perspectives on data monitoring in clinical trials in drug development. , 1993, Statistics in medicine.
[9] Kenneth R. Hess,et al. Extensions and Applications of Event Charts , 2000 .
[10] P. Thall,et al. Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. , 1995, Statistics in medicine.